.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
Harvard Business School
US Army
QuintilesIMS
US Department of Justice
Express Scripts
Dow
Merck
Medtronic

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,632,787

« Back to Dashboard

Details for Patent: 8,632,787

Title:Methods using immunomodulatory compounds for treatment of certain leukemias
Abstract: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention. The invention further relates to methods of treatment using an immunomodulatory compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Dec 02, 2011
Application Number:13/310,543
Claims:1. A method of treating a patient having acute myeloid leukemia, which comprises (a) administering to said patient a therapeutically effective amount of cytarabine and from about 5 mg per day to about 25 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione having the formula: ##STR00009## or a pharmaceutically acceptable salt, or solvate thereof wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered for 21 days followed by a period of rest; and (b) repeating step (a).

2. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 5 mg per day.

3. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 10 mg per day.

4. The method according to claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 15 mg per day.

5. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered in an amount of 25 mg per day.

6. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered orally.

7. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered as a free base.

8. The method of claim 1, wherein the cytarabine is administered subcutaneously or intravenously.

9. The method of claim 1, wherein the cytarabine is administered once or twice daily in an amount of from about 10 to about 375 mg.

10. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered cyclically in a four or six week cycle.

11. The method of claim 1, wherein the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is administered orally in an amount of about 10 mg per day for twenty-one days followed by a period of time of rest of each cycle.

12. The method of claim 1, wherein the cytarabine and the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or the pharmaceutically acceptable salt, solvate or stereoisomer thereof are administered concurrently.

13. The method of claim 1, wherein the cytarabine and the 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or the pharmaceutically acceptable salt, solvate or stereoisomer thereof are administered sequentially.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Merck
McKinsey
Express Scripts
Novartis
Moodys
AstraZeneca
Fuji
Chinese Patent Office
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot